Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?

MLA

Möhring, Christian, et al. “Efficacy and Tolerability of Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Unselected Patients with Advanced Gastric and Gastroesophageal Cancer: Does Age Really Matter?” Journal of Cancer Research and Clinical Oncology, vol. 149, no. 5, May 2023, pp. 1849–62. EBSCOhost, https://doi.org/10.1007/s00432-022-04109-8.

APA

Möhring, C., Timotheou, A., Mańczak, A., Sadeghlar, F., Zhou, T., Mahn, R., Bartels, A., Monin, M., Toma, M., Feldmann, G., Brossart, P., Köksal, M., Sarria, G. R., Giordano, F. A., Lingohr, P., Jafari, A., Kalff, J. C., Strassburg, C. P., & Gonzalez-Carmona, M. A. (2023). Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter? Journal of Cancer Research and Clinical Oncology, 149(5), 1849–1862. https://doi.org/10.1007/s00432-022-04109-8

Chicago

Möhring, Christian, Aliki Timotheou, Adrianna Mańczak, Farsaneh Sadeghlar, Taotao Zhou, Robert Mahn, Alexandra Bartels, et al. 2023. “Efficacy and Tolerability of Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Unselected Patients with Advanced Gastric and Gastroesophageal Cancer: Does Age Really Matter?” Journal of Cancer Research and Clinical Oncology 149 (5): 1849–62. doi:10.1007/s00432-022-04109-8.